Efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ of bladder

Acta Urologica Japonica

Volumn 52, Issue 6, 2006, Pages 439-444

  Uekado, Yasunari ^a   Kohjimoto, Yasuo ^a   Iba, Akinori ^a   Kikkawa, Kazurou ^a   Shintani, Yasuyo ^a   Shinka, Toshiaki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

BCG; Bladder cancer; Carcinoma in situ

Indexed keywords

BCG VACCINE; BROPIRIMINE; GEMCITABINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CARCINOMA IN SITU; CASE REPORT; CONTROLLED STUDY; CYSTECTOMY; DRUG EFFICACY; FOLLOW UP; HUMAN; MALE; PROSTATE CANCER; TREATMENT RESPONSE; URINARY DIVERSION; URINARY TRACT CANCER;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA IN SITU; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 33745742675     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Kim JC and Steinberg GD: The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. J Urol 165: 745-756, 2001
2. Morales A, Eidinger D and Bruce AW: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116: 180-183, 1976
3. Hudson MA and Herr HW: Carcinoma in situ of the bladder. J Urol 153: 564-572, 1995
4. Nadler RB, Catalona WJ, Hudson MA, et al.: Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol 152: 367-373, 1994
5. Joudi FN and O'Donnell MA: Secondline intravesical therapy versus cystectomy for bacillus Calmette-Guerin (BCG) failures. Curr Opin Urol 14: 271-275, 2004
6. Donat SM: Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am 30: 765-776, 2003
7. Dalbagni G, Russo P, Sheinfeld J, et al.: Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 20: 3193-3198, 2002
8. Lamm DL: Carcinoma in situ. Urol Clin North Am 19: 499-508, 1992
9. Herr HW, Wartinger DD, Fair WR, et al.: Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol 147: 1020-1023, 1992
10. Catalona WJ, Hudson MA, Gillen DP, et al.: Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 137: 220-224, 1987
11. Coplen DE, Marcus MD, Myers JA, et al.: Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J Urol 144: 652-657, 1990
12. Herr HW, Badalament RA, Amato DA, et al.: Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 141: 22-29, 1989
13. Herr HW and Dalbagni G: Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 169: 1706-1708, 2003
14. Herr HW:Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette- Guerin therapy. J Urol 174: 2134-2137, 2005
15. Harland SJ, Charig CR, Highman W, et al.: Outcome in carcinoma in situ of bladder treated with intravesical bacillus Calmette-Guerin. Br J Urol 70: 271-275, 1992
16. Bui TT and Schellhammer PF: Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 49: 687-691, 1997
17. Bretton PR, Herr HW, Kimmel M, et al.: The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin. J Urol 143: 710-713, 1990
18. O'Donnell MA, Krohn J and DeWolf WC: Salvage intravesical therapy with interferon-α2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 166: 1300-1305, 2001
19. O'Donnell MA, Lilli K, Leopold C, et al.: Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172: 888-893, 2004
20. Berger AP, Steiner H, Stenzl A, et al.: Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 61: 338-341, 2003
21. Steinberg G, Bahnson R, Brosman S, et al.: Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J Urol 163: 761-767, 2000
22. Mckienan JM, Murphy Am, Goetzl M, et al.: Phase I trial of intravesical docetaxel in the treatment of superficial bladder cancer resistant to standard intravesical therapy. J Urol 173: 247, 2005
23. De Jager R, Guinan P, Lamm D, et al.: Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette-Guerin: overview analysis of six phase II clinical trials. Urology 38: 507-513, 1991
24. Cookson M, Herr HW, Zhang Z-F, et al.: The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158: 62-67, 1997
25. Klein EA, Rogatko A and Herr HW: Management of local bacillus Calmette-Guerin failures in superficial bladder cancer. J Urol 147: 601-606, 1992
26. Amling C, Thrasher JB, Fraizier H, et al.: Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151: 31-36, 1994